| Company Name | Gilead Sciences Hong Kong Ltd. Taiwan Branch |
|---|---|
| Protocol Number | GS-TW-540-5928 |
| Title of Study | A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan |
| Primary Objective | The primary objective of this study is to assess the overall safety profile of Veklury in COVID-19 patients, including deaths. |
| Number of Sites | 5 |
| Period of Study | From：2021/08/03 to：2025/Q1 |
| Number of Patients | 100人 |
| IRB Approval Date | National Taiwan University Hospital – 25May2021 Taoyuan General Hospital – 04Aug2021 Taichung Veterans General Hospital – 02Jun2021 Tri-Service General Hospital – 17Jun2021 Chang Gung Medication Foundation – Linkou Branch – 23Jun2021 |
| Publication Plan / Date | No publication planned at this moment. |
